Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease-Hebei Province,China,November 2018 to November 2020  

作　　者：Yan Li Pingshu Zhang Zhijie An Ying Ma Yamin Wang Liye Wang Yunqiu Liu Xiaodong Yuan Keli Li Zundong Yin Huaqing Wang 

机构地区：[1]National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing,China [2]Kailuan General Hospital,Tangshan City,Hebei Province,China

出　　处：《China CDC weekly》2023年第20期452-458,I0003,共8页中国疾病预防控制中心周报（英文）

基　　金：National Key R&D Program of China(2017YFC1309304).

摘　　要：Summary What is already known on this topic?Chronic obstructive pulmonary disease(COPD)exacerbations increase household economic burden,but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden.What is added by this report?This study demonstrated the economic burden of COPD exacerbations,pneumonia,and hospitalization in COPD patients in China is substantial.Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine(PPSV23),separately or together,were significantly associated with decreased economic burden.What are the implications for public health practice?Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.

关 键 词：IMPACT BURDEN Hebei 

分 类 号：R563.1[医药卫生—呼吸系统]